Karyopharm Announces FDA Approval of XPOVIOĀ® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Claimed Company
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions read more
Kirk Schamp ā Vice President, Head of Market Access at Karyopharm Therapeutics
Executive Bio
Kirk Schamp serves as the Vice President, Head of Market Access of Karyopharm Therapeutics Inc.. Kirk started at Karyopharm Therapeutics Inc. in September of 2017. Kirk currently resides in the Greater Atlanta Area.
Executive Team Culture Ratings from Karyopharm Therapeutics Employees
TOP
15%
Karyopharm Therapeutics' Executive Team scores in the Top 15%
of similar sized companies on Comparably
of similar sized companies on Comparably
Karyopharm Therapeutics' Executive Team at a Glance
Based on 178 ratings, Karyopharm Therapeutics' employees are very satisfied with their Executive Team and give them an āA-ā or 80/100. On average, Men provided higher ratings for their Executive Team compared to Women. Also, the Other department thinks more highly of the Executive Team relative to the Clinical Operations department.
Karyopharm Therapeutics' Executive Team ranks in the Top 20% of other companies in Boston and Top 15% of other companies on Comparably that also have 201-500 Employees.
×